EUVIMEDEUVIMED entdecken
Crossref

Management of limited stage Hodgkin lymphoma

Shruthi Kodad

Canadian Hematology Today · 2023

DOI: 10.58931/cht.2023.2123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Hematology Today, 2023. Verfasst von Shruthi Kodad. Die Arbeit nennt 21 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hodgkin lymphoma (HL) is a lymphoid neoplasm characterized by malignant lymphocytes, known as Reed-Sternberg cells, on a background of non-neoplastic inflammatory cells. Lugano staging determines the stage of Hodgkin lymphoma, which, in turn, determines the treatment and prognosis. Limited-stage disease is defined as Stage I and Stage II, which is diagnosed in more than 50% of patients. Pre-treatment risk stratification, PET-adapted therapy, and combined modality treatment have significantly improved cure rates, making limited-stage HL one of the most curable malignancies. In this article, we discuss the current approach to managing limited-stage HL.

Zitieren

APA

Kodad, S. (2023). Management of limited stage Hodgkin lymphoma. Canadian Hematology Today. https://doi.org/10.58931/cht.2023.2123

Vancouver

Kodad S. Management of limited stage Hodgkin lymphoma. Canadian Hematology Today. 2023. doi:10.58931/cht.2023.2123

BibTeX
@article{Kodad2023,
  author = {Kodad, Shruthi},
  title = {Management of limited stage Hodgkin lymphoma},
  journal = {Canadian Hematology Today},
  year = {2023},
  doi = {10.58931/cht.2023.2123}
}
Kostenlos starten →